Comparative Diagnostic Utility of Metagenomic Next-generation Sequencing, GeneXpert, Modified Ziehl-Neelsen Staining, and Culture Using Cerebrospinal Fluid for Tuberculous Meningitis: A multi-center, Retrospective Study in China
Overview
Biotechnology
Pathology
Authors
Affiliations
Background: Early diagnosis of tuberculosis meningitis (TBM) remains a great challenge during clinical practice. The diagnostic efficacies of cerebrospinal fluid (CSF)-based mycobacterial growth indicator tube (MGIT) culture, modified Ziehl-Neelsen (ZN) staining, Xpert MTB/RIF, and metagenomic next-generation sequencing (mNGS) for TBM remained elusive.
Methods: A total of 216 adult patients with suspicious TBM were retrospectively enrolled in this multi-cohort study. The diagnostic performances for MGIT, modified ZN staining, Xpert MTB/RIF, and mNGS using CSF samples were evaluated.
Results: Uniform clinical case definition classified 88 (40.7%) out of 216 patients as the definite TBM, 5 (2.3%) patients as probable TBM cases, and 24 (11.1%) patients as possible TBM cases. The sensitivities of MGIT, modified ZN staining, Xpert MTB/RIF, and mNGS for TBM diagnosis against consensus uniform case definition for definite TBM were 25.0%, 76.1%, 73.9%, and 84.1%, respectively. Negative predictive values (NPVs) were 66.0%, 85.9%, 84.8%, and 90.1%, respectively. The sensitivities of MGIT, modified ZN staining, Xpert MTB/RIF, and mNGS for TBM diagnosis against consensus uniform case definition for definite, probable, and possible TBM were 18.8%, 57.3%, 55.5%, and 63.2%, respectively. Negative predictive values (NPVs) were 51.0%, 66.4%, 65.6%, and 69.7%, respectively. mNGS combined with modified ZN stain and Xpert could cover TBM cases against a composite microbiological reference standard, yielding 100% specificity and 100% NPV.
Conclusion: Metagenomic next-generation sequencing detected TBM with higher sensitivity than Xpert, ZN staining and MGIT culture, but mNGS cannot be used as a rule-out test. mNGS combined with Xpert or modified ZN staining could enhance the sensitivity of diagnostic tests for TBM.
Niu M, Bai Z, Dong L, Zheng W, Wang X, Dong N Clin Med Res. 2025; 22(4):197-205.
PMID: 39993828 PMC: 11849970. DOI: 10.3121/cmr.2024.1869.
Tuberculous meningitis diagnosis and treatment: classic approaches and high-throughput pathways.
Lin F Front Immunol. 2025; 15:1543009.
PMID: 39867878 PMC: 11757110. DOI: 10.3389/fimmu.2024.1543009.
Chen X, Liang Y, Yang W, He W, Xing Z, Li S Front Cell Infect Microbiol. 2025; 14():1386377.
PMID: 39844841 PMC: 11751054. DOI: 10.3389/fcimb.2024.1386377.
Nanopore-targeted sequencing (NTS) for intracranial tuberculosis: a promising and reliable approach.
Yang C, Wang T, Guo Y, Zeng Y, Gao W Ann Clin Microbiol Antimicrob. 2024; 23(1):89.
PMID: 39385187 PMC: 11466032. DOI: 10.1186/s12941-024-00751-x.
Zhou L, Zou X, Yong Y, Hu Q BMJ Open. 2024; 14(6):e080904.
PMID: 38862231 PMC: 11168130. DOI: 10.1136/bmjopen-2023-080904.